← All trials
NCT00442598
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- Apr 1, 2008
- Completion date
- Apr 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 17
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Eleison PharmaceuticalsLead sponsor
- University of ArizonaOverall official - principal investigator
- New Mexico Cancer Care AllianceOverall official - principal investigator
- Premiere OncologyOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- California Cancer CenterOverall official - principal investigator
- Gabrail Cancer CenterOverall official - principal investigator
- Harrington Cancer CenterOverall official - principal investigator
- Eleison PharmaceuticalsOverall official - principal investigator
- University of LouisvilleOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.